GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (STU:ANUA) » Definitions » Cyclically Adjusted FCF per Share

XORTX Therapeutics (STU:ANUA) Cyclically Adjusted FCF per Share : €-1.91 (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is XORTX Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

XORTX Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2025 was €-0.160. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-1.91 for the trailing ten years ended in Mar. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2025-05-23), XORTX Therapeutics's current stock price is €0.834. XORTX Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was €-1.91. XORTX Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


XORTX Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for XORTX Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics Cyclically Adjusted FCF per Share Chart

XORTX Therapeutics Annual Data
Trend Feb15 Feb16 Feb17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -2.05

XORTX Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.08 -2.14 -2.12 -2.05 -1.91

Competitive Comparison of XORTX Therapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, XORTX Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XORTX Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XORTX Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where XORTX Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


;
;

XORTX Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, XORTX Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.16/129.1809*129.1809
=-0.160

Current CPI (Mar. 2025) = 129.1809.

XORTX Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201505 -0.011 100.263 -0.014
201508 -0.098 100.579 -0.126
201511 -1.604 100.421 -2.063
201602 -0.068 100.421 -0.087
201605 -0.149 101.765 -0.189
201608 -0.030 101.686 -0.038
201611 -0.558 101.607 -0.709
201702 -0.132 102.476 -0.166
201705 -0.183 103.108 -0.229
201708 -0.251 103.108 -0.314
201711 -0.136 103.740 -0.169
201803 -1.132 105.004 -1.393
201806 -0.281 105.557 -0.344
201809 -0.257 105.636 -0.314
201812 -0.052 105.399 -0.064
201903 -0.119 106.979 -0.144
201906 -0.047 107.690 -0.056
201909 0.017 107.611 0.020
201912 -0.124 107.769 -0.149
202003 -1.934 107.927 -2.315
202006 -0.230 108.401 -0.274
202009 -0.139 108.164 -0.166
202012 1.224 108.559 1.457
202103 -0.851 110.298 -0.997
202106 -0.574 111.720 -0.664
202109 -0.020 112.905 -0.023
202112 -2.036 113.774 -2.312
202203 -1.578 117.646 -1.733
202206 -1.247 120.806 -1.333
202209 -0.681 120.648 -0.729
202212 -1.683 120.964 -1.797
202303 -1.213 122.702 -1.277
202306 -0.803 124.203 -0.835
202309 -0.506 125.230 -0.522
202312 -0.600 125.072 -0.620
202403 -0.495 126.258 -0.506
202406 -0.239 127.522 -0.242
202409 -0.241 127.285 -0.245
202412 -0.259 127.364 -0.263
202503 -0.160 129.181 -0.160

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


XORTX Therapeutics  (STU:ANUA) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


XORTX Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


XORTX Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

XORTX Therapeutics Headlines

No Headlines